Physician profile
Paul Belany
NPI 1528448917
$3,018.50
in general payments reported to CMS, 2019-2025
18 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $152 · 2021: $348 · 2022: $647 · 2023: $619 · 2024: $408 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $776.64 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $552.67 | 2022-2025 | Mounjaro, Zepbound, Humulin |
| Novo Nordisk INC | $475.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $379.58 | 2020-2022 | |
| Boston Scientific Corporation | $145.12 | 2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $141.86 | 2022-2023 | Freestyle Libre 2, Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.13 | 2022-2025 | Jardiance, Synjardy |
| Tandem Diabetes Care, INC. | $92.14 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $75.55 | 2022-2025 | |
| Pfizer INC. | $57.81 | 2024 | |
| Xeris Pharmaceuticals, INC. | $44.76 | 2022-2025 | Recorlev |
| Corcept Therapeutics | $32.20 | 2025 | Korlym |
| Amryt Pharma Holdings Ltd | $31.31 | 2022-2023 | Mycapssa |
| Amgen INC. | $27.78 | 2020 | |
| Medtronic, INC. | $18.79 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $15.64 | 2022 | |
| Merck Sharp & Dohme LLC | $15.05 | 2022 | |
| Evoke Pharma, INC. | $13.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Belany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.